PartneringOur Capabilities

Why Recordati as a Partner

Recordati was founded in 1926 in Italy and is today a well-established European specialty pharmaceutical group that thanks to its own R&D activities, to partnerships and to acquisitions has grown into a European mid-sized player with a strong and growing interest in emerging markets.
We have:
  • Commercial presence in Western, Southern and Eastern Europe:
  1. affiliates in Western Europe (Italy, France, Germany, Greece, Portugal, Spain, United Kingdom & Ireland), and Central Eastern Europe (Poland, the Czech Republic, Slovakia, Romania) as well as Russia and the other CIS countries, plus Turkey thus serving about 80% of the EU market;
  2. a strong team of over 1800 well experienced sales & marketing professionals.
  • Orphan Europe and Recordati Rare Diseases are the group’s wholly owned subsidiaries dedicated to the development and sale of drugs for the treatment of rare diseases. These comprise a dedicated pan-European organization complemented by a commercial presence in the Middle East, in Japan, an organization in the USA and commercial presence in various other countries. Genuinely Recordati’s orphan business is today a global one.
  • Proven R&D experience in developing drugs treating cardiovascular, urology and metabolic diseases. Examples include both original drugs (lercanidipine, fenticonazole, flavoxate) as well as in-licensed products (cariprazine, silodosin, pitavastatin, vitaros and fortacin).
  • Proven capabilities in the management of regulatory procedures and clinical trials in the EU, MENA and the USA.
  • Extensive know-how and full industrial resources covering the manufacturing chain, from active ingredient to finished product (facilities in Italy, France, Ireland, Spain, Czech Republic, Turkey and Tunisia).
  • Financially sound to support R&D investments.
  • Long-standing track record and commitment to partnering.